Cookie notice

We use cookies to personalize content and ads. They inter alia facilitate the provision of our services and help us with the payout of editorial and advertising content, and the analysis of user conduct in order to optimize our website. By using our services, you agree that we may use cookies. For further information please click here.

description

Hamamatsu Photonics

MTIF

Medical Technologies Innovation Facility

  • MTIF

     

    Hamamatsu Photonics UK Ltd and Medical Technologies Innovation Facility (MTIF) are pleased to announce they have entered into a partnership agreement enabling customers the ability to view and utilise Hamamatsu’s Functional Drug Screening System (FDSS) µCELL.

    Through this new technical collaboration, Hamamatsu and MTIF will organically integrate their respective advanced technologies and development capabilities to showcase this novel laboratory screening technology onsite at MTIF in Nottingham, UK.

     

    For more information and to view the full press release please click here.

     

    What is the FDSS®/μCELL?

    The FDSS/μCELL is a compact, easy to use screening system that enables monitoring of GPCRs and ion channels for drug discovery and life science research. Screening various compounds at high throughput (96 / 384 well assays) is enabled by fluorescence or luminescence measurements using a highly sensitive Hamamatsu camera, which captures cell dynamics under the same conditions with no time lag between wells. It is also capable of recording changes in electrical potential in iPSC-derived neuronal and cardiac stem cells to gain a better understanding of toxic compound effects.

     

    How to get involved?

    Medical Technologies Innovation Facility (MTIF) is a new medical devices and advanced materials convergent technology organisation, with a strong academic pedigree and expertise in pioneering cell therapy research and development. MTIF are excited to offer its customers access  to the novel Hamamatsu FDSS µCell laboratory screening technology onsite at its Nottingham, UK facility. With a wealth of experience and capabilities MTIF is here to identify and individualise support for  your high throughput live cell assays and imaging needs supporting drug development, basic research and cell line development. MTIF stands behind the quality of results delivered and builds strong customer partnerships. Rest assured arising Intellectual Property generated by the work conducted by MTIF remains our customers property. 

     

    Hamamatsu and MTIF would like to work with customers to accelerate drug discovery and life science research through use of the FDSS/μCELL. If you think your research might benefit from the FDSS/μCELL, please get in touch with the Hamamatsu or MTIF team.

     

    Contact Us

    To request further information or to discuss any technical queries regarding the FDSS/μCELL please contact Emma King, FDSS Sales Engineer, Hamamatsu.

     

    Emma King, FDSS Sales Engineer, Hamamatsu - eking@hamamatsu.co.uk, 01707 294 888

    Max Bardwell, Senior Business Development Manager, MTIF - max.bardwell@ntu.ac.uk, +44 7717 224731

     

    Contact Us by Email

    Resources:

    Hamamatsu Introduction to the FDSS (Functional Drug Screening Systems) and CYTOQUBE (High Content Screening (HCS) system)

     

    A brief overview of our Functional Drug Screening Systems (FDSS) and an introduction to the CYTOQUBE, from Hamamatsu Photonics, which are state of the art instruments used for applications such as GPCR, ion channel, protein-protein interaction and toxicity assays within the life science, biomedical and pharmaceutical research industries. Please enquire via our website for more information or a conversation about your objectives and requirements.

    See the link to our FDSS product line-up: https://www.hamamatsu.com/jp/en/product/life-science-and-medical-systems/drug-screening-system/index.html

    Plus here is a link to our FDSS applications page: https://fdss.hamamatsu.com/jp/en/index.html

    News of the CYTOQUBE can be found here along with a link to download the full tech release document: https://www.hamamatsu.com/jp/en/news/featured-products_technologies/2019/20190610000000.html

     

    WEBINAR: Cell Therapies: Bench to Bedside - Hamamatsu's High Throughput Screening (HTS) of stem cells using the FDSSµCell

     

    Hamamatsu Photonics' talk on the High Throughput Screening (HTS) of stem cells using the FDSSµCell at the Cell Therapies: Bench to Bedside webinar discusses how the FDSSµCell can benefit research in the field of cell therapy using two case studies as examples; one on disease modelling using cardiomyocytes to investigate diabetes and another using the unique Electric Field Stimulation (EFS) function of the FDSSµCell to look at the characteristics of myoblasts. This short video clip should give you an idea of how you can carry out your cell therapy research using the FDSSµcell at the Medical Technologies Innovation Facility (MTIF) facility.

     

    WEBINAR: Cell Therapies: Bench to Bedside - Medical Technologies Innovation Facility (MTIF)'s part in accelerating cellular therapies

     

    A talk given by Professor John Hunt, from the Medical Technologies Innovation Facility (MTIF), at the Cell Therapies: Bench to Bedside webinar, focusing on how cell therapies could be the magic bullet for treating many different and previously intractable diseases. John speaks about how creating a new cell therapy can be fraught with complexities, from sourcing, growing and transporting cells, and the ways MTIF use their understanding of cellular interactions with substrates and tools such as the FDSSµCell to evaluate in-vitro biocompatibility at their facility.

     

    Please note, any contact information collected will be shared between Hamamatsu Photonics UK Limited and the Medical Technologies Innovation Facility.